Cost-Utility Analysis of a Complex Intervention to Reduce School-Based Bullying and Aggression: An Analysis of the Inclusive RCT.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
01 2021
Historique:
received: 24 10 2019
revised: 19 03 2020
accepted: 06 04 2020
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 7 4 2021
Statut: ppublish

Résumé

Bullying and aggression among children and young people are key public mental health priorities. In this study, we evaluated the cost-effectiveness of a complex school-based intervention to address these outcomes within a large-cluster randomized trial (Inclusive). Forty state secondary schools were randomly allocated (1:1) to receive the intervention or continue with current practice as controls. Data were collected using paper questionnaires completed in classrooms including measures of their health-related quality of life using the Childhood Utility Index and police and National Health Service resource use. Further detailed data were collected on the cost of delivering the intervention. We calculated incremental cost-effectiveness ratios following the intention-to-treat principle using multilevel linear regression models that allowed for clustering of pupils at the school level. Overall, we found that the intervention was highly cost-effective, with cost-per quality-adjusted life year thresholds of £13 284 and £1875 at 2 years and 3 years, respectively. Analysis of uncertainty in the result at 2 years revealed a 65% chance of being cost-effective, but after 3 years there was a 90% chance that it was cost-effective. This study provides strong evidence collected prospectively from a randomized study that this school-based intervention is highly cost-effective. Education- and health-sector policy makers should consider investment in scaling up this intervention.

Identifiants

pubmed: 33431147
pii: S1098-3015(20)32214-2
doi: 10.1016/j.jval.2020.04.1839
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-135

Subventions

Organisme : Department of Health
ID : 12/153/60
Pays : United Kingdom

Informations de copyright

Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Rosa Legood (R)

London School of Hygiene & Tropical Medicine, Keppel Street, London, England, United Kingdom. Electronic address: rosa.legood@lshtm.ac.uk.

Charles Opondo (C)

London School of Hygiene & Tropical Medicine, Keppel Street, London, England, United Kingdom.

Emily Warren (E)

London School of Hygiene & Tropical Medicine, Keppel Street, London, England, United Kingdom.

Farah Jamal (F)

London School of Hygiene & Tropical Medicine, Keppel Street, London, England, United Kingdom.

Chris Bonell (C)

London School of Hygiene & Tropical Medicine, Keppel Street, London, England, United Kingdom.

Russell Viner (R)

UCL Great Ormond St. Institute of Child Health, 30 Guilford Street, London, England, United Kingdom.

Zia Sadique (Z)

London School of Hygiene & Tropical Medicine, Keppel Street, London, England, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH